Investors State Shareholder Proposal at Special Meeting to Effectuate Material Changes in Board of Directors May Be Required
Sheridan, Wyo., September 28, 2022 /PRNewswire/ — FCM MM HOLDINGS, LLC (“FCM”) announces today that it has received a letter (the “Letter”) to the board of directors (the “Board of Directors”) of Mind Medicine (MindMed) Inc. MNMD (“MindMed” or the “Company”) informs the Board of Directors of FCM that it has strongly opposed the Company’s announced public offering September 27, 2022 (the “Dilution Offer”). In the letter, FCM explains how board and management actions, including the dilution offer, have destroyed shareholder value, calls on the board to end the offer immediately, and commits to taking action to hold the board accountable .
“We undertake to take all necessary measures to protect the interests of shareholders”
“We are committed to taking all necessary steps to protect the interests of shareholders and we look forward to engaging in a zealous voting rights campaign,” said FCM’s chief executive manager Jake Freeman.
The full text of the letter is available and can be downloaded at mindmed.zone/letterdilution
About FCM
FCM is managed by Jake Freeman and represents an investment of 6.1% of MindMed’s outstanding shares.
FCM also represents other early investors in MindMed including Scott Freeman and Chad Boulangerall of whom have a strong interest in MindMed’s long-term success.
For more disclosures related to public service applications, see mindmed.zone/disclosure
media contact
Jake Freeman
Managing Director
FCM MM HOLDINGS, LLC
30 N Gould St St R
Sheridan, Wy 82801
Phone: 908-308-2381
E-mail: jake@mindmed.zone
SOURCE FCM MM Holdings, LLC
